Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17064920 | 0.78 | CTSK (0.33) | CTSKMGLLDRD4 | |
| SCHEMBL17064922 | 0.78 | CTSK (0.33) | CTSKMGLLDRD4 | |
| SCHEMBL18623209 | 0.78 | CTSK (0.33) | CTSKMGLLDRD4 | |
| SCHEMBL21919218 | 0.76 | GSK3B (0.39) | DRD4 | |
| SCHEMBL21919223 | 0.76 | MGLL (0.32) | CTSKMGLL | |
| SCHEMBL31067700 | 0.76 | AHR (0.40) | CTSKAHRCNR2MGLLDRD4 | |
| SCHEMBL17064418 | 0.76 | AHR (0.40) | CTSKAHRCNR2MGLLDRD4 | |
| SCHEMBL21919194 | 0.75 | SIGMAR1 (0.38) | — | |
| SCHEMBL17073502 | 0.73 | CTSK (0.38) | CTSKAHRCNR2MGLLDRD4 | |
| SCHEMBL25784088 | 0.71 | MAPT (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685721-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685721-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | CTSK 52/4885AHR 4449/4885CNR2 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.